Índices Morfológicos na Nefrite Lúpica: Orientação Prognóstica? Um Estudo Retrospetivo

David NAVARRO1, Ana Carina FERREIRA1, Helena VIANA1, Fernanda CARVALHO1, Fernando NOLASCO1

RESUMO
Introdução: A nefrite lúpica é uma complicaçãograve do lúpus eritematoso sistêmico. Atualmente, a terapêutica dirigida é dita pelos achados histológicos da biópsia renal, através da classificação da International Society of Nephrology / Renal Pathology Society. Os índices histomorfológicos descritos por Austin e Hill não são routineiramente realizados. Neste estudo retrospectivo univariado, procuramos analisar a aplicabilidade e relevância dos índices morfológicos na predição da resposta à terapêutica e do prognóstico em doentes com nefrite lúpica.

Material e Métodos: Foram incluídos doentes cuja biópsia renal, realizada entre 2010 e 2016, documentava nefrite lúpica. Analisámos os dados demográficos, comorbilidades, apresentação clínica e avaliação laboratorial destes doentes correspondente à altura da biópsia renal. Avaliámos os seguintes outcomes: remissão clínica, função renal e proteinúria no final do seguimento. A avaliação histológica foi realizada segundo a classificação da International Society of Nephrology / Renal Pathology Society e aplicando os índices morfológicos descritos por Austin (Actividade e Cronicidade) e Hill. A análise estatística univariada e multivariada foi realizada com software STATA.

Resultados: Foram revistos 46 casos de nefrite lúpica, com um follow-up mediano de 31,9 (13,2 – 45,6) meses. A partir dos achados histológicos, 35 doentes foram submetidos a imunossupressão. Observámos que os doentes com nefrite lúpica Classe IV tinham, à apresentação, taxa de filtrado glomerular estimada mais reduzida (67,3 vs 94,6 mL/min; p = 0,02), proteinúria mais elevada (4,26 vs 2,37 g/24 horas; p = 0,02) e consumo de C3 mais elevado de modo não-significativo (58,9 vs 77,4 mg/dL; p = 0,06). Não se verificou correlação entre a classificação ISN/RPS e os desfechos no final do follow-up. Por outro lado, tanto o índice de Hill quanto o score de chronicidade de Austin correlacionaram-se com a função renal e a proteinúria no final do seguimento. Adicionalmente, o score de atividade de Austin correlacionou-se com os achados imunológicos à apresentação (C3, C4 e anti-dsDNA). 

Discussão: Uma vez que a atividade clínica tem fraca correlação com a atividade histológica, os achados histológicos são fundamentais durante a avaliação na suspeita de nefrite lúpica. A mais recente revisão da International Society of Nephrology / Renal Pathology Society vai ao encontro das linhas de orientação da European League Against Rheumatism, encurtando a aplicação de índices histomorfológicos na avaliação da nefrite lúpica. Os dados da nossa população, onde verificámos uma correlação entre o prognóstico renal e os índices histomorfológicos descritos por Austin e Hill, apoiam esta sugestão.
INTRODUCTION

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease associated with significant comorbidity and mortality. Lupus nephritis (LN) is one of its most serious complications and includes a wide spectrum of clinical presentations, ranging from isolated haematuria to serious complications and includes a wide spectrum of morphological indexes; these have been originally described by Austin and Hill et al, who defined two indexes (activity and chronicity), using a semi-quantification of findings. This was further studied by Hill et al, who modified previous indexes, improving its prognostic value. Subcategorization of class III and IV into active, chronic or both is also suggested to be replaced by this semi-quantification method.

Histomorphology has been of paramount importance in defining the field of nephrology. The quantification of microscopy findings has found its place in renal transplantation. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) lupus nephritis classification is widely used and recommended in current guidelines. Histology findings allow the sub-classification into six classes (I – VI), as shown in Table 1. The most recent report and EULAR guidelines additionally recommend the use of morphological indexes; these have been originally described by Austin et al, who defined two indexes (activity and chronicity), using a semi-quantification of findings. This was further studied by Hill et al, who modified previous indexes, improving its prognostic value. Subcategorization of class III and IV into active, chronic or both is also suggested to be replaced by this semi-quantification method.

MATERIAL AND METHODS

This is a retrospective single-centre descriptive analysis of consecutive SLE and biopsy-proven LN patients, diagnosed from 2010 to 2016. Patients whose kidney biopsies were found to be inadequate due to an insufficient number of glomeruli (defined as less than five) were excluded.

Table 1 – Abbreviated lupus nephritis ISN/RPS classification

<table>
<thead>
<tr>
<th>Class</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Minimal mesangial lupus nephritis</td>
</tr>
<tr>
<td>Class II</td>
<td>Mesangial proliferative lupus nephritis</td>
</tr>
<tr>
<td>Class III</td>
<td>Focal lupus nephritis</td>
</tr>
<tr>
<td>Class IV</td>
<td>Diffuse lupus nephritis</td>
</tr>
<tr>
<td>Class V</td>
<td>Lupus membranous nephropathy</td>
</tr>
<tr>
<td>Class VI</td>
<td>Advanced sclerosing lupus nephritis</td>
</tr>
</tbody>
</table>

Patients’ data were obtained from clinical files. We analyzed patients’ demographic data (age, gender, race), comorbidities and their duration (including SLE history and previous manifestations and medications), hypertension according to the most recent definition by the European Society of Cardiology, clinical presentation and laboratorial evaluation at the time of renal biopsy [including full blood count, serum creatinine, urinalysis, proteinuria (24 hours-collection or urinary protein to creatinine ratio in a random urine sample), C3, C4 and anti-dsDNA].

The following outcomes were evaluated: clinical remission, renal function and proteinuria (g/24 hours) at end of follow-up (FUP). The LUNAR trial definition for clinical remission was used: complete remission was defined as reduction of proteinuria to < 0.5 g/24 hours, inactive urinary sediment and normal serum creatinine level if it was abnormal at baseline (or a serum creatinine level of < 115% of baseline if it was normal at baseline); partial remission was defined as a reduction in proteinuria to < 1 g/24 hours if initial level < 3 g/24 hours or reduction to < 3 g/24 hours if initial level > 3 g/24 hours), inactive urinary sediment and a serum creatinine level of < 115% of baseline. All renal biopsies were performed after obtaining the patient’s written consent. The histologic optic examination was performed with hematoxylin and eosin, periodic acid–Schiff, Jones’ silver and Masson’s trichrome stains; immunofluorescence study included studies with antibodies against IgG, IgA, IgM, C3, C4, C1q and fibrinogen.

The studied predictors were the ISN/RPS LN classification and the morphological indexes described by Austin (activity and chronicity) and Hill, obtained after histomorphological review of renal biopsies. Both scores describe findings in a quantitative fashion (zero to 3+). Austin’s activity score measures active LN findings of glomerular proliferation, leucocyte exudation/karyorrhexis, fibrinoid necrosis, cellular crescents, hyaline deposits and interstitial inflammation; Austin’s chronicity score contains chronic irreversible LN findings: glomerular sclerosis, fibrous crescents, tubular atrophy and interstitial fibrosis.

Hill’s biopsy index slightly adapted Austin’s activity and chronicity scores and added histological signs of tubulointerstitial activity (including tubular cell necrosis and flattening and the presence of macrophages or epithelial cells in tubular lumens) and immunofluorescence findings (including glomerular, tubulointerstitial and vascular deposition). Regarding the latter, in the review of our samples, we did not re-perform immunofluorescence and instead used the findings described in our original report.

Renal function was monitored by serum creatinine and estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Conclusão: Os índices histomorfológicos na nefrite lúpica são de fácil aplicação, conseguem prever os outcomes clinicos e podem representar uma ferramenta adicional na avaliação dos doentes com nefrite lúpica.

Palavras-chave: Biópsia; Lupus Eritematoso Sistêmico/complicações; Nefrite Lúpica; Prognóstico; Rim/patologia; Valor Preditivo dos Testes
Data are presented as frequencies for categorical variables; continuous variables are presented as median (interquartile range). One-way ANOVA was used for comparisons between the different indications for kidney biopsy, the laboratory data and the morphologic data obtained after the application of the different morphological indexes; chi-square test of independence/Fisher’s exact test was performed when comparing the different indications for kidney biopsy and the ISN/RPS LN classes. Associations between the different LN classes and clinical and laboratory variables were investigated using Fisher’s exact test and Wilcoxon. Associations between Austin and Hill indexes and laboratory variables were investigated using Spearman test.

After this first analysis, we fitted a model of multivariate analysis using all subjects and defining the chronicity indexes as our main predictors and eGFR at the end of follow-up as our main outcome. Age, gender and proteinuria were the variables used as potential confounders (older patients may have a lower renal function, women tend to have lower GFR and proteinuria is associated with a rapid decline of renal function). All tests were performed using STATA software version 13, and a p-value < 0.05 was considered statistically significant.

Given the nature of this analysis (retrospective and observational) and the anonymization of the collected data, authorization from the ethics committee and the Portuguese Data Protection Authority was not required.

### RESULTS

From 2010 to 2016, we found 46 biopsy-proven LN cases in our unit. The patients’ median age was 35 years (27 – 42), and 84.8% (n = 39) were women, in a mostly Caucasian population (56.5%; n = 26). In seven patients, SLE diagnosis was previously unknown, while the remaining 39 patients had SLE for a median of 3.96 (1.1 – 11.9) years, resulting in treatment with hydroxychloroquine in 46.1% and additional immunomodulation in 76.9% of cases. At presentation, median creatinine was 0.8 (0.6 – 1.4) mg/dL, corresponding to a median eGFR of 89 (46.9 – 117) mL/min; median level of proteinuria was 2.45 (1 – 4.4) g/day; 34.7% (n = 16) of patients were hypertensive and 58.7% (n = 27) had haematuria at presentation. We classified our patients according to the indication for renal biopsy: 18 had asymptomatic urinary abnormalities, 16 nephrotic-range proteinuria (proteinuria > 3.5 g/d) and 12 renal insufficiency (eGFR < 45 ml/min). The histomorphological findings are summarized in Table 3.

Regarding histology, sample quality was adequate, the minimum number of glomeruli per sample was five and we had a maximum of 30 glomeruli, with a median of 11 glomeruli per sample. The patients’ median age was 35 years (27 – 42), and 84.8% (n = 39) were women, in a mostly Caucasian population (56.5%; n = 26). In seven patients, SLE diagnosis was previously unknown, while the remaining 39 patients had SLE for a median of 3.96 (1.1 – 11.9) years, resulting in treatment with hydroxychloroquine in 46.1% and additional immunomodulation in 76.9% of cases. At presentation, median creatinine was 0.8 (0.6 – 1.4) mg/dL, corresponding to a median eGFR of 89 (46.9 – 117) mL/min; median level of proteinuria was 2.45 (1 – 4.4) g/day; 34.7% (n = 16) of patients were hypertensive and 58.7% (n = 27) had haematuria at presentation. We classified our patients according to the indication for renal biopsy: 18 had asymptomatic urinary abnormalities, 16 nephrotic-range proteinuria (proteinuria > 3.5 g/d) and 12 renal insufficiency (eGFR < 45 ml/min). The histomorphological findings are summarized in Table 3.

Regarding histology, sample quality was adequate, the minimum number of glomeruli per sample was five and we had a maximum of 30 glomeruli, with a median of 11 glomeruli (7.75 – 14.25). The 46 patients were evaluated during a median follow-up of 31.9 months (13.2 – 45.6) months.

### Table 3 – Renal clinical characteristics and histomorphology findings

<table>
<thead>
<tr>
<th>Clinical presentation</th>
<th>Patients</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
<th>Class V</th>
<th>Austin's Activity Index</th>
<th>Austin's Chronicity Index</th>
<th>Hill Biopsy Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic urinary abnormalities</td>
<td>18</td>
<td>44%</td>
<td>17%</td>
<td>28%</td>
<td>11%</td>
<td>3.03 (0 – 6)</td>
<td>1.50 (0 – 2.63)</td>
<td>0.86</td>
</tr>
<tr>
<td>Nephrotic syndrome (proteinuria &gt; 3.5 g/d)</td>
<td>16</td>
<td>0%</td>
<td>25%</td>
<td>63%</td>
<td>31%</td>
<td>6.59 (1.65 – 10)</td>
<td>2.66 (1 – 3)</td>
<td>1.83</td>
</tr>
<tr>
<td>Renal insufficiency (eGFR &lt; 45 ml/min)</td>
<td>12</td>
<td>0%</td>
<td>8%</td>
<td>75%</td>
<td>17%</td>
<td>6.95 (0.5 – 13)</td>
<td>3.73 (0.5 – 7)</td>
<td>1.96</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt; 0.001</td>
<td>NS</td>
<td>0.02</td>
<td>NS</td>
<td>0.07</td>
<td>0.08</td>
<td>0.007</td>
<td></td>
</tr>
</tbody>
</table>

eGFR: estimated glomerular filtration rate; NS: non-significant. LN Classes (from II to V) frequencies are expressed for each renal clinical characteristic (asymptomatic urinary abnormalities | nephrotic syndrome | renal disease). Median indexes (Austin activity and chronicity and Hill biopsy) are expressed for each renal clinical characteristic (asymptomatic urinary abnormalities | nephrotic syndrome | renal disease). The analysis of the proportions between renal characteristics and LN classes was performed using Fisher exact test; the analysis of the variance of the different indexes was performed using one-way ANOVA.
Based on biopsy findings, immunosuppressive therapy was started/intensified on 36 patients — induction therapy with cyclophosphamide in 50% and methylprednisolone (MMF) in the remaining 50%; MMF was used as maintenance therapy in 80.6% (n = 29) of patients, azathioprine being the choice for the other seven patients. Excluding patients with ongoing induction immunosuppression, clinical remission was obtained in 93.8% (30/32) of patients — we observed 15 complete, 15 partial remissions and four patients suffered LN recurrence.

By the end of follow-up, two patients (4.3%) died due to septic shock, one of them having developed end-stage renal disease secondary to LN. The remaining 95.7% (n = 44) had a median serum creatinine of 0.8 mg/dL (0.7 – 0.99), eGFR of 99.8 mL/min (71.2 – 116.8) and proteinuria of 0.6 g/24 hours (0.2 – 1.6).

Using Wilcoxon test, we observed that patients classified as ISN/RPS class IV had, at presentation, lower eGFR of 9.3 mg/dL (3.7 – 0.99), eGFR of 9.8 mL/min (71.2 – 116.8) and proteinuria of 0.6 g/24 hours (0.2 – 1.6).

Using the Spearman test, we observed that the Activity index correlated with the immunological findings at presentation — C3, C4 and anti-dsDNA. More importantly, both the Activity and Chronicity index were correlated with histological findings at the end of follow-up and the activity and chronicity morphological indexes, as described in Table 4.

Using the Spearman test, we observed that the Activity index correlated with the immunological findings at presentation — C3, C4 and anti-dsDNA. More importantly, both the Activity and Chronicity index were correlated with histological findings at the end of follow-up and the activity and chronicity morphological indexes, as described in Table 4.

Table 4 – Correlations between clinical parameters and histomorphological indexes

<table>
<thead>
<tr>
<th></th>
<th>Austin’s Activity Index</th>
<th>Austin’s Chronicity Index</th>
<th>Hill Biopsy Index</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>p</td>
<td>R</td>
</tr>
<tr>
<td>Presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA (IU/mL)</td>
<td>0.3</td>
<td>0.05</td>
<td>-0.07</td>
</tr>
<tr>
<td>C3 (mg/dL)</td>
<td>-0.3</td>
<td>0.03</td>
<td>0.1</td>
</tr>
<tr>
<td>C4 (mg/dL)</td>
<td>-0.3</td>
<td>0.04</td>
<td>0.1</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>0.1</td>
<td>NS</td>
<td>0.3</td>
</tr>
<tr>
<td>eGFR (mL/min)</td>
<td>-0.3</td>
<td>NS</td>
<td>-0.4</td>
</tr>
<tr>
<td>Proteinuria (g/24h)</td>
<td>0.4</td>
<td>0.009</td>
<td>-0.3</td>
</tr>
<tr>
<td>End of follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>0.07</td>
<td>NS</td>
<td>0.4</td>
</tr>
<tr>
<td>eGFR (mL/min)</td>
<td>0.09</td>
<td>NS</td>
<td>-0.5</td>
</tr>
<tr>
<td>Proteinuria (g/24h)</td>
<td>0.2</td>
<td>NS</td>
<td>0.3</td>
</tr>
</tbody>
</table>

eGFR: estimated glomerular filtration rate. All correlations were made using Spearman correlation in a univariate analysis.

DISCUSSION

Management of SLE patients can be complex, being especially challenging to attain disease control without causing iatrogenesis. For this reason, many efforts are put into the elaboration and refining of disease activity indexes. The same holds true for LN, especially since some of the clinical parameters we rely on for renal disease (serum creatinine and proteinuria) can represent both active disease — that may be treated with further immunosuppression — and chronic damage — which would not benefit from additional immunomodulation. For those reasons, clinical remission definitions in LN are many and rarely agreed upon. More importantly, clinical activity poorly correlates with histologic activity, further complicating clinical decisions. To mitigate this, some centers are routinely performing repeat renal biopsies regardless of clinical indication.

Nephrologists rely heavily on histomorphological findings in LN, and general agreement is that immunosuppression should be started when the ISN/RPS classification suggests the patient has an active proliferative disease (class III or IV with activity signs) or a severe membranous LN (class V); treating renal affection with immunosuppressive drugs for other classes is typically not recommended. Some limitations to the ISN/RPS classification need to be considered, starting with the fact that it is, by definition,glomerulocentric, leaving little to no space to the description of the full spectrum of histomorphological manifestations of LN. This confers an almost dichotomic-aura (i.e. treat / don’t treat) to the current classification and hampers the introduction of diagnostic subtleties such as lupus podocytopathy. Another issue is that while nephrologists are sensible to findings such as tubular atrophy and interstitial fibrosis, until the last update, ISN/RPS failed to account for tubulointerstitial lesions adequately. Injury to the tubulointerstitial compartment appears to poorly correlate with glomerular lesions, suggesting independent immunological pathways, which were oversimplified by the ISN/RPS classification — this raises the question if the tubulointerstitial activity should itself be an indication for immunosuppressive therapy.
therapy. Furthermore, and perhaps most importantly, there is an increasing body of evidence showing that tubulointerstitial lesions are the most significant prognostic indicator in LN. It is therefore not surprising that, despite being extensively used, the ISN/RPS classification could not predict clinical outcomes. This has led to the development of the indexes described by Austin and later by Hill, which have proven capable of estimating renal outcomes from the renal biopsy findings. Their integration in the most recent ISN/RPS classification reflects its importance. In an era of a continuous search for more sophisticated therapeutic strategies, it’s surprising that so little emphasis had been given to improve upon our current clearly insufficient diagnostic methods. Despite being ‘old news’, morphological indexes have the potential to introduce a more refined approach to diagnosis and treatment, similar to what the Banff criteria offer to the renal transplantation field.

Our first goal was to evaluate the applicability of such scores: despite not being familiar with them and requiring an additional effort, we had no substantial difficulty in their application. The second goal was to evaluate their usefulness in predicting response to treatment and prognosis. As shown in Table 3, we observed an association between clinical presentation and the ISN/RPS classification. The same is valid for Hill’s biopsy index and Austin’s Activity and Chronicity indexes. However, when considering outcomes at the end of follow-up, the ISN/RPS classification added little, while the morphological indexes can predict outcomes (Table 4).

Based on these findings, although we feel morphological indexes are useful in LN, some limitations are observable: i) we only reviewed light microscopy findings and did not re-perform immunofluorescence; ii) it is a retrospective single-centre study, with a fairly low number of patients limiting our conclusions — for instance, we would have liked to further examine the role of the indexes with different immunosuppressive drugs, which were not apparent in our population. Further analysis with a larger number of patients could shed some light on this subject, potentially identifying the patients who require a more aggressive therapeutic approach.

CONCLUSION

In summary, the most recent ISN/RPS consensus recognizes the efficacy of histomorphological indexes in the evaluation of LN, and our data supports that. We observed a significant correlation between the renal outcomes and the indexes described by Austin and Hill. We encourage other units to include morphological indexes in their evaluation of such patients, as they are easily applicable scores and may provide a useful and individualized quantitative measure of clinical outcomes.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association.

DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working centre regarding patients’ data publication.

CONFLICTS OF INTEREST

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

FUNDING SOURCES

The authors received no financial support for the research, authorship, and/or publication of this article.

REFERENCES


